ABL Bio Inc. (KOSDAQ:298380)

Market Cap	5.17T +72.8%
Revenue (ttm)	90.32B +226.9%
Net Income	-24.14B
EPS	-452.97
Shares Out	55.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	584,554
Open	88,400
Previous Close	88,600
Day's Range	85,800 - 97,700
52-Week Range	60,700 - 257,500
Beta	0.21
Analysts	Buy
Price Target	223,200.00 (+141.56%)
Earnings Date	Aug 11, 2026

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson’s disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatm...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2016
• Employees: 102
• Stock Exchange: KOSDAQ
• Ticker Symbol: 298380

Financial Performance

In 2025, ABL Bio's revenue was 79.35 billion, an increase of 137.55% compared to the previous year's 33.40 billion. Losses were -37.81 billion, -31.92% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for 298380 stock is "Buy." The 12-month stock price target is ₩223,200, which is an increase of 141.56% from the latest price.

Price Target

₩223,200

(141.56% upside)

Analyst Consensus: Buy